2.2亿元关联资金拆借惹祸！嘉应制药被罚

Core Points - Jia Ying Pharmaceutical received an administrative penalty from the China Securities Regulatory Commission for illegal information disclosure and related party transactions [1][2][3] - The company and its chairman, Li Neng, were involved in short-term fund lending to a related party, Yao Juneng, without proper disclosure and approval [1][2] - The company reported a significant decline in revenue and net profit over the past two years, with 2024 revenue dropping by 29.46% year-on-year [3][4] Group 1: Regulatory Actions - Jia Ying Pharmaceutical was fined 1.5 million yuan, while Li Neng was fined 1.6 million yuan, totaling 4.9 million yuan in penalties for the violations [2] - The Guangdong Securities Regulatory Bureau issued a warning letter to the company for failing to disclose financial assistance and related party transactions [2][3] - The company acknowledged the violations and committed to enhancing compliance awareness [2] Group 2: Financial Performance - In 2024, Jia Ying Pharmaceutical's revenue was 37.6 million yuan, a decrease of 29.46% year-on-year, and the net profit dropped by 39.94% to 20.61 million yuan [3] - The company's gross margin fell from 75.31% in 2021 to 59.93% in 2024, indicating a declining profitability trend [3] - For the first three quarters of 2025, the company reported a revenue of 29.3 million yuan, a year-on-year increase of 13.0%, and a net profit of 21.79 million yuan, a significant increase of 658.5% [3][4]